Ona Therapeutics Raises $86.6M Series B to Advance ADC Pipeline

Why It Matters

The infusion of $86.6 million positions Ona to compete in the fast‑growing ADC space, potentially delivering novel therapies for metastatic solid tumors and attracting further partnership or exit opportunities. Success would validate its target‑discovery platform and accelerate investor interest in European biotech ADC innovators.

Key Takeaways

• Ona secured $86.6 million Series B to fund ADC development.
• Lead candidate ONA‑255 targets undisclosed antigen, heading to clinical trials.
• Pipeline includes ONA‑389, another ADC from proprietary discovery platform.
• Funding follows 2020 €30 million Series A (~$33 million) round.
• ADCs are a fast‑growing modality for solid‑tumor oncology.

Pulse Analysis

The antibody‑drug conjugate market has surged in the past five years, driven by breakthroughs in linker chemistry, payload potency, and antibody engineering. Investors are chasing platforms that can pair a high‑affinity antibody with a cytotoxic payload while maintaining stability in circulation. Ona’s recent $86.6 million Series B places it among a select group of European biotech firms that have secured sizable late‑stage capital to move ADC candidates from bench to bedside, underscoring the sector’s appetite for novel solid‑tumor solutions.

Ona’s lead asset, ONA‑255, is described as a first‑in‑class ADC, suggesting a unique target or novel conjugation strategy that could differentiate it from existing products such as Kadcyla or Enhertu. Although the antigen is undisclosed, the company’s origin in metastasis biology hints at a target involved in tumor spread, a high‑unmet‑need area. The parallel programme ONA‑389 expands the pipeline, leveraging the same discovery engine that identified CD36 for the earlier ONA‑01 antibody. By diversifying across multiple ADCs, Ona mitigates risk while showcasing the versatility of its platform.

From a business perspective, the Series B not only funds clinical‑grade manufacturing and regulatory work but also signals confidence to potential partners and acquirers. As major pharma players continue to outsource early ADC development, Ona could become an attractive partner for co‑development or licensing deals. Moreover, the transition from a €30 million Series A focused on metastasis to a $86.6 million ADC‑centric raise reflects a strategic pivot toward a modality that promises higher valuation multiples and faster paths to market, positioning Ona for a potentially lucrative exit within the next decade.

Deal Summary

Barcelona-based Ona Therapeutics announced it has closed a $86.6 million Series B financing round to fund the development of its next-generation antibody-drug conjugates, including the ONA-255 program. The capital will support the transition from preclinical research to clinical execution of its ADC pipeline. Founded in 2019 as a spin-off from IRB Barcelona and ICREA, the company aims to bring first-in-class ADCs to market.